美国ZOLL Medical  www.zoll.com
美国卓尔医学产品公司 (ZOLL Medical Corporation) 专业致力于研发和生产急救复苏产品与解决方案。ZOLL拥有完善的除颤起搏技术和产品，并已发展成为涵括自动心肺复苏，急救低温管理，液体复苏，急救信息系统等全方位急救技术的专业公司。ZOLL的产品和技术帮助您更好应对从院前急救、院内急诊、公共场所现场急救、灾难救援、直到战地救护等各种复杂急救需要，并为病患提供最及时和先进的生命急救保障。
AED Plus 自动体外除颤仪 
AED Pro 自动体外除颤仪 
AutoPulse 自动心肺复苏系统
E Series 除颤仪 
R Series 除颤仪
M Series 除颤仪
M Series CCT 除颤仪
除颤电极片
SurePower 除颤仪电池管理系统
Power Infuser 快速输液泵 
用于整合火警和 EMS 急救的 RescueNet 数据管理软件
CodeNet 复苏数据管理系统

Thermogard XP 温度管理系统
IVTM 导管系列
除颤仪操控板软件
ZOLL 早期除颤仪
2012年旭化成(Asahi Kasei)22亿美元收购卓尔医学 

China
Daniel Sun, Director
1st Floor, No. 7 Building
#439Chun Xiao Road
Zhang Jiang Hightech Park
Shanghia, 201203, China
+86 21 5027 8567 Telephone
+86 21 5027 8519 Fax
+86 139 119 01586 Mobile
email: dsun@zoll.com 

ZOLL Medical Corporation, a leader in medical products and software solutions, helps responders manage, treat, and save lives in emergency rescues and in hospitals; outside the hospital while at work or home; in doctors' and dentists' offices and schools; in public places and on the battlefield. ZOLL's products contribute to managing patient care and savings lives, as well as increasing the efficiency of emergency medical, fire and hospital operations around the globe:
ALS defibrillators like R Series® for hospitals and E Series® for EMS, with real-time CPR feedback
LifeVest®, the world's first and only wearable automatic defibrillator
Temperature management technology for managing core body temperature of critically ill or surgical patients
AutoPulse®, a revolutionary non-invasive cardiac support pump that moves more blood more consistently than possible with manual chest compressions
RescueNet® software helps simplify the capture, sharing and accuracy of data
Automated external defibrillators (AEDs) that help BLS providers and lay bystanders provide defibrillation and the best possible chest compressions if only CPR is required 
1952 While Chief of the Cardiac Clinic at Beth Israel Hospital, Paul M. Zoll, M.D., demonstrates that external electrical stimulation of a patient’s chest during cardiac arrest could produce an effective heartbeat.
1956 • Is the first physician to successfully use external defibrillation to regulate heart rhythms in patients. This discovery contributes significantly to the decrease in heart disease mortality.
• With technical collaborators, Dr. Zoll develops a way to display the heart’s cardiac electrical activity on an oscilloscopic screen. This includes registering each heartbeat with an audible signal, and sounding an alarm at the onset of cardiac arrest. These developments lead to cardiac monitors and other programs found in modern cardiac care units.
1960
Discovers that external electrical countershock is effective in terminating supraventricular tachycardia and ventricular tachycardia. This procedure becomes widely used in the treatment of these arrhythmias, and is found to be safer than administering large doses of antiarrhythmic drugs.
1964
Develops a method for long-term direct electrical heart stimulation through an implanted pacemaker. Implanted cardiac pacemakers derive from his technologic breakthrough and are today a major cardiac therapy. It is estimated that more than 500,000 patients in the U.S. today are kept alive by implanted pacemakers.
1973
Receives the Albert Lasker Award for Clinical Medical Research, also known as "America's Nobels.” The Lasker Award is for physicians and others whose accomplishments made major advances in the understanding, diagnosis, prevention, and treatment of major life-threatening diseases. It is most coveted award in medical science.
1977
Becomes Clinical Professor of Medicine, Emeritus, at Harvard Medical School.

ZOLL Medical Corporation: The Early Beginnings
1980
ZOLL is incorporated by the company’s three co-founders, Dr. Zoll, Willard M. Bright, and Rolf Stutz.
1983
Company introduces the ZOLL NTP® 1000, a non-invasive temporary pacemaker based on Dr. Zoll’s research. This patented technology provides superior capture rates, better patient tolerance of external pacing, and a clear recognition of cardiac capture.
1986
• The American Heart Association’s National Conference on Cardiopulmonary Resuscitation and Emergency Cardiac Care includes non-invasive external cardiac pacing as an adjunct to advanced cardiac life support.
• ZOLL introduces pediatric non-invasive pacing technology.
1988
Launches the ZOLL PD 1200™ Pacemaker/Defibrillator/Monitor, the first to combine proven pacing and defibrillating technology in a reliable, easy-to-use, compact unit. The operator can choose between monitoring, pacing, and defibrillation with just the turn of one control knob.
1989
Introduces adult multi-function electrodes, which provide well-tolerated pacing, effective defibrillation, cardioversion, and monitoring—all through a single pair of pre-gelled disposable electrodes.
 
ZOLL Medical Corporation: An Innovator In Resuscitation
1992
• Becomes a public company with an initial public offering of 2.1 million shares, which generates $14.6 million.
• Releases the PD 1400 Pacemaker/Defibrillator/Monitor, the smallest and lightest device of its kind available for critical patient transport and pre-hospital treatment.
• The American Heart Association elevates the importance of non-invasive pacing to the initial treatment of choice for certain serious patient conditions (Class 1 for profound bradycardia). ZOLL is the market leader for this technology.
• The American Heart Association Guidelines strongly recommend, “defibrillators be immediately available to emergency personnel responding to a cardiac arrest,” both in hospital and prehospital settings. It also emphasizes that the most important factor contributing to patient survival is the speed in delivering treatment.
1994
Receives 510(k) marketing clearance from the FDA for the PD/D 2000 automated external defibrillator (AED)/advisory defibrillator.
1995
• Establishes a subsidiary in The Netherlands.
• Receives ISO 9001 Certification, essential for marketing products in many European countries. This is an important endorsement of the quality of ZOLL’s products and manufacturing practices.
• Announces a distribution agreement covering ZOLL’s products in Germany, the largest European market for resuscitation products.
• Launches ZOLL 1600, the first fully upgradeable and configurable AED/manual external defibrillator. Small, light, and easy to use, the ZOLL 1600 is suitable for first responders, EMTs, and paramedics.
• The U.S. Navy equips its major surface vessel hospitals and on-board medical facilities exclusively with the ZOLL PD 2000.
• Introduces the first modular AC power supply/battery charger for hospital devices for use on the ZOLL 1400, 1600, and 2000 family of defibrillators.
1996
• Acquires Westech Mobile Solutions, allowing ZOLL to add software-based information products to its prehospital product line.
• Makes an equity investment in LIFECOR, Inc., a medical equipment company that makes the LifeVest®, the first and only wearable defibrillator.
• Introduces the ZOLL 1700, the first fully integrated AED/manual external defibrillator for hospital BLS and ACLS use.
• Announces the new Base PowerCharger™ 4x4 to address common battery reliability issues. It is the first system in the industry to offer a complete and practical solution for improving the reliability, effectiveness, and cost of battery management.
1997
• Launches RescueNet®, the only complete EMS information management system that helps improve patient care, operational efficiency, and agency compliance. RescueNet, manufactured by ZOLL Data Systems, is used by hundreds of EMS organizations.
• Unveils a tablet computer-based 12-lead system to help identify the onset of cardiac arrest.
1998
Introduces the M Series®, the most advanced defibrillator worldwide. The product weighs 11 pounds, and is approximately one third the size and half the weight of any competitive full-featured defibrillator. The M Series is the first to provide a bright, high-contrast display of cardiac rhythms, a critical capability for any emergency unit.
1999
• Establishes subsidiaries in Canada and Germany.
• Announces the revolutionary Rectilinear Biphasic™ defibrillation waveform, which lowers the energy needed for successful defibrillation and cardioversion. In a unique development, the FDA clears ZOLL’s new biphasic waveform to be labeled as clinically superior to monophasic defibrillators for the conversion of ventricular fibrillation in high-impedance patients and for cardioversion of atrial fibrillation. ZOLL is the first company to have FDA clearance to make such superiority claims since the development of defibrillation in the 1950s.
• Acquires Pinpoint Technologies to provide a complete information management solution to the EMS market.
• Introduces “Smart Batteries,” an industry first. Smart Batteries provide users with accurate run times directly displayed on the battery. This development eliminates time-consuming testing procedures and minimizes user error.
2001
• Establishes subsidiaries in Australia and France.
• Launches the M Series® CCT for critical care transport.
• The ZOLL AED Plus® is designed in cooperation with the Burlington, Mass. Police Department and hundreds of other first responders and EMS agencies.
2002
• Receives 510(k) marketing clearance from the FDA for its AED Plus and the new CPR-D•padz®. This is the first system to provide instantaneous feedback on the depth and rate of chest compressions during CPR.
• ZOLL provides an initial grant to help establish the AED Instructor Foundation.
• The M Series CCT is selected as the defibrillator of choice for the U.S. Military Patient Movement Item Program. The agreement, worth $8.9 million, is the single largest order in ZOLL’s history.
• ZOLL and LIFECOR, Inc. announce an agreement to sell LIFECOR’s LifeVest Wearable Defibrillator to hospitals for patient use in the United States and Canada.
2003
• Announces a relationship with Advanced Circulatory Systems, Inc. to bring the ResQPOD® Circulatory Enhancer to market.
• Enters into an agreement with Revivant Corporation to commercialize the AutoPulse® Non-invasive Cardiac Support Pump, a new FDA-approved portable device that automates chest compressions, and increases blood flow to the brain and heart more consistently than manual CPR.
• The AED Plus wins First Place in Product Design and Development magazine’s prestigious 2003 Engineering Awards Program.
2004
• Establishes a subsidiary in Austria.
• Renames its Pinpoint Technologies subsidiary ZOLL Data Systems® to better reflect the EMS market.
• Acquires Infusion Dynamics, Inc., which manufactures a unique fluid resuscitation product called the Power Infuser®.
• Pediatric capability for the ZOLL AED Plus receives 510(k) marketing clearance from the FDA.
• Launches CodeNet®, the first complete data management system that solves the problem of hard-to-manage code event data for hospitals.
2005
• Introduces the ZOLL AED Pro® for professional rescuers.
• ZOLL launches the E Series®, ZOLL’s newest defibrillator designed to meet the specific demands and extreme conditions of the EMS environment (temperature, moisture, and portability).
2006
• ZOLL completes the acquisition of the assets of Lifecor, Inc., a privately owned medical equipment company, which designs, manufactures and markets the LifeVest Wearable Defibrillator.
• ZOLL launches the R Series®, the first and only “Code-Ready®” defibrillator for hospitals.
2007
• ZOLL receives market clearance for E Series® with Real CPR Help® technology.
• ZOLL receives clearance to market E Series with See-Thru CPR® technology; functionality helps minimize interruptions in CPR.
• ZOLL named one of Forbes Most Trustworthy companies in America for the first time.
• ZOLL purchases the temperature management assets of Radiant Corporation.
• ZOLL receives clearance to market AED Pro with See-Thru CPR technology; helps minimize interruptions in CPR.
• ZOLL surpasses $300 million mark in revenues.
2008
• ZOLL marks 25th anniversary.
• First hands-only CPR AED Plus
• STEMI solutions offer enhanced transmission technology for 12-lead EKG.
• AED Pro receives airworthy designation.
• RescueNet® ePCR suite designated NEMSIS Gold Compliant Software.
• AutoPulse approved for use in China.
• LifeVest Wearable Defibrillator exceeds 10,000 prescriptions.
• R Series Code-Ready® defibrillator awarded highest value score in the U.K.
• ZOLL and Welch-Allen enter strategic alliance; ZOLL becomes exclusive distributor of Propaq® LT.
• ZOLL has record annual results. Reaches $398 million in revenues; up 29 percent over previous year.
2009
• First State of Resuscitation Survey ranks bystander CPR, faster patient-to-doctor times, data collection and technology as critical improvement areas for resuscitation.
• ZOLL is one of only ten companies on Forbes Top 100 Most Trustworthy Companies list for all three years of its publication.
• LifeVest wearable defibrillator prescribed by doctors at all U.S. Honor Roll Hospitals.
• ZOLL purchases intravascular temperature management (IVTM™)assets from Alsius Corporation.
• New R Series BLS and R Series Plus receive FDA clearance.
2010
• ZOLL awarded British Heart Foundation tender for AEDs.
• Propaq® MD monitor/defibrillator and Propaq M monitor granted 510(k) clearance by the FDA
• Brazil Ministry of Health awards ZOLL AED contract for the country’s public EMS system.
• ZOLL LifeVest® Wearable Defibrillator physician prescriptions top 30,000.
• ZOLL LifeVest Wearable Defibrillator prescribed by physicians at all U.S. News and World Report “Honor Roll Hospitals” for third consecutive year.
• ZOLL’s resuscitation technology strongly aligned with the new AHA/ERC/ILCOR 2010 Guidelines’ emphasis on high-quality CPR and minimizing interruptions in chest compressions.
• Swiss Air Rescue, Rega, the first international installation, and PHI Air Medical of Phoenix, Arizona, the first North American installation, of the ultra lightweight Propaq MD Monitor/Defibrillator.
• Nine SCA survivors saved with the help of ZOLL devices among 50 survivors selected to attend 50th anniversary of CPR celebration in San Diego.
 
2011
• AutoPulse CIRC (Circulation Improving Resuscitation Care) trial concludes successfully; first large scale resuscitation trial to reach a statistically significant result.
• ZOLL receives Frost & Sullivan 2010 Market Leadership Award for demonstrated excellence in capturing the highest market share the North American external defibrillator market.
• Physician prescriptions for ZOLL LifeVest top 35,000.
• PocketCPR® FOR iPhone training app first to support new 2010 AHA/ERC/ILCOR Guidelines.
• ZOLL launches iPad app for ePCR; EMS teams can now use iPad technology to complete electronic patient care reports.
• Australia’s NSW Rural Fire Service, world’s largest volunteer fire fighting agency, orders more than 5,000 AED Plus units for state wide initiative.
• ZOLL honored with 10th successive Omega NorthFace ScoreBoard Award? for excellence in technical support and customer service.
• Welsh Ambulances NHS Trust awards ZOLL largest contract to date for the E Series in the U.K.
• ZOLL reports record second quarter revenue and earnings.